{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:19:37Z","timestamp":1773674377530,"version":"3.50.1"},"reference-count":44,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2018,6,30]]},"DOI":"10.5582\/ddt.2018.01017","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T18:22:50Z","timestamp":1531160570000},"page":"142-153","source":"Crossref","is-referenced-by-count":6,"title":["D-cycloserine nasal formulation development for anxiety disorders by using polymeric gels"],"prefix":"10.5582","volume":"12","author":[{"given":"Yeonoh","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Thomas Jefferson University"},{"name":"Pensylvania State University, Old Main, State College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutika","family":"Kokate","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Thomas Jefferson University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilas","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Thomas Jefferson University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Bhushan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Thomas Jefferson University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagan","family":"Kaushal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, Thomas Jefferson University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. L\u00e9pine JP. The epidemiology of anxiety disorders: Prevalence and societal costs. J Clin Psychiatry. 2002; 63:4-8."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Rodrigues H, Figueira I, Lopes A, Gon\u00e7alves R, Mendlowicz MV, Coutinho ESF, Ventura P. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PloS One. 2014; 9:e93519.","DOI":"10.1371\/journal.pone.0093519"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999; 60:427-435.","DOI":"10.4088\/JCP.v60n0702"},{"key":"4","doi-asserted-by":"crossref","unstructured":"5. Tomek SE, LaCrosse AL, Nemirovsky NE, Olive MF. NMDA receptor modulators in the treatment of drug addiction. Pharmaceuticals. 2013; 6:251-268.","DOI":"10.3390\/ph6020251"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001; 158:1367-1377.","DOI":"10.1176\/appi.ajp.158.9.1367"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999; 56:21-27.","DOI":"10.1001\/archpsyc.56.1.21"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004; 161:2115-2117.","DOI":"10.1176\/appi.ajp.161.11.2115"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004; 61:1136-1144.","DOI":"10.1001\/archpsyc.61.11.1136"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006; 63:298-304.","DOI":"10.1001\/archpsyc.63.3.298"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11. Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, Rowley T, Welsh KS, Wilhelm S. Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with D-cycloserine. Behav Res Ther. 2010; 48:675-679.","DOI":"10.1016\/j.brat.2010.03.007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiat. 2007; 62:835-838.","DOI":"10.1016\/j.biopsych.2006.12.020"},{"key":"12","unstructured":"13. Conzelman GM Jr. The physiologic disposition of cycloserine in the human subject. Am Rev Tuberc. 1956; 74:739-746."},{"key":"13","unstructured":"14. Nair C, Ray A, Singh J. Studies on Nuri strain of P. knowlesi. XI. Comparative studies on quinine and chloroquine administered intravenously. Indian J Malariol. 1956; 10:85-93."},{"key":"14","unstructured":"15. Baron H, Epstein IG, Mulinos MG, Nair KG. Absorption, distribution, and excretion of cycloserine in man. Antibiot Annu. 1955; 3:136-140."},{"key":"15","unstructured":"16. Crofton J, Chaulet P, Maher D, <i>et al<\/i>. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997 (Publication no. WHO\/GTB\/96.210.)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Kaushal G, Ramirez R, Alambo D, Taupradist W, Choksi K, Sirbu C. Initial characterization of D-cycloserine for future formulation development for anxiety disorders. Drug Discov Ther. 2011; 5:253-260.","DOI":"10.5582\/ddt.2011.v5.5.253"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Dahlin M, Bergman U, Jansson B, Bj\u00f6rk E, Brittebo E. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res. 2000; 17:737-742.","DOI":"10.1023\/A:1007542618378"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. Dahlin M, Bj\u00f6rk E. Nasal absorption of (S)-UH-301 and its transport into the cerebrospinal fluid of rats. Int J Pharm. 2000; 195:197-205.","DOI":"10.1016\/S0378-5173(99)00392-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"21. van Berckel BN, Lipsch C, Timp S, Gispen-de Wied C, Wynne H, Van Ree J, Kahn R. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology. 1997; 16:317-324.","DOI":"10.1016\/S0893-133X(96)00196-0"},{"key":"20","unstructured":"22. Wen MM. Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: Current development. Discov Med. 2011; 11:497-503."},{"key":"21","doi-asserted-by":"crossref","unstructured":"23. Qian S, Wong YC, Zuo Z. Development, characterization and application of <i>in situ<\/i> gel systems for intranasal delivery of tacrine. Int J Pharm. 2014; 468:272-282.","DOI":"10.1016\/j.ijpharm.2014.04.015"},{"key":"22","doi-asserted-by":"crossref","unstructured":"24. Md S, Haque S, Fazil M, Kumar M, Baboota S, Sahni JK, Ali J. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: Biodistribution, pharmacokinetic and dopamine estimation by ultraHPLC\/mass spectrometry method. Expert Opin Drug Deliv. 2014; 11:827-842.","DOI":"10.1517\/17425247.2014.894504"},{"key":"23","doi-asserted-by":"crossref","unstructured":"25. Chaturvedi M, Kumar M, Pathak K. A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res. 2011; 2:215-222.","DOI":"10.4103\/2231-4040.90876"},{"key":"24","doi-asserted-by":"crossref","unstructured":"26. Kissel T, Werner U. Nasal delivery of peptides: An <i>in vitro<\/i> cell culture model for the investigation of transport and metabolism in human nasal epithelium. J Control Release. 1998; 53:195-203.","DOI":"10.1016\/S0168-3659(97)00253-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"27. Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 2011; 3:89.","DOI":"10.4103\/0975-7406.76478"},{"key":"26","unstructured":"28. Narasimharao R, Anusha Reddy M, Swetha Reddy N, Divyasagar P, Keerthana K. Design and evaluation of metformin hydrochloride extended release tablets by direct compression. Int J Res Pharm Biomed Sci. 2011; 2:1118-1133."},{"key":"27","doi-asserted-by":"crossref","unstructured":"29. Brime B, Ballesteros M, Frutos P. Preparation and <i>in vitro<\/i> characterization of gelatin microspheres containing Levodopa for nasal administration. J Microencapsul. 2000; 17:777-784.","DOI":"10.1080\/02652040050161765"},{"key":"28","doi-asserted-by":"crossref","unstructured":"30. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005; 57:1640-1665.","DOI":"10.1016\/j.addr.2005.07.009"},{"key":"29","doi-asserted-by":"crossref","unstructured":"31. Fini A, Bergamante V, Ceschel GC. Mucoadhesive gels designed for the controlled release of chlorhexidine in the oral cavity. Pharmaceutics. 2011; 3:665-679.","DOI":"10.3390\/pharmaceutics3040665"},{"key":"30","doi-asserted-by":"crossref","unstructured":"32. Williams RO, Sykora MA, Mahaguna V. Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets. AAPS PharmSciTech. 2001; 2:29-37.","DOI":"10.1208\/pt020208"},{"key":"31","unstructured":"34. Sharwaree H, Priyanka B, Ashok B, Swapnil M. Development of mucoadhesive nasal <i>in situ<\/i> gel to sustain the release of amitriptyline hydrochloride. Int J Biol Pharm Res. 2012; 3:980-989."},{"key":"32","doi-asserted-by":"crossref","unstructured":"35. El-Kamel A. <i>In vitro<\/i> and <i>in vivo<\/i> evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm. 2002; 241:47-55.","DOI":"10.1016\/S0378-5173(02)00234-X"},{"key":"33","doi-asserted-by":"crossref","unstructured":"36. Ibrahim el-SA, Ismail S, Fetih G, Shaaban O, Hassanein K, Abdellah NH. Development and characterization of thermosensitive pluronic-based metronidazole <i>in situ<\/i> gelling formulations for vaginal application. Acta Pharm. 2012; 62:59-70.","DOI":"10.2478\/v10007-012-0009-y"},{"key":"34","doi-asserted-by":"crossref","unstructured":"37. Carotenuto C, Grizzuti N. Thermoreversible gelation of hydroxypropylcellulose aqueous solutions. Rheologica Acta. 2006; 45:468-473.","DOI":"10.1007\/s00397-005-0075-x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"38. Chen E, Chen J, Cao SL, Zhang QZ, Jiang XG. Preparation of nasal temperature-sensitive <i>in situ<\/i> gel of Radix Bupleuri and evaluation of the febrile response mechanism. Drug Dev Ind Pharm. 2010; 36:490-496.","DOI":"10.3109\/03639040903264371"},{"key":"36","doi-asserted-by":"crossref","unstructured":"39. Joshi SC. Sol-gel behavior of hydroxypropyl methylcellulose (HPMC) in ionic media including drug release. Materials (Basel). 2011; 4:1861-1905.","DOI":"10.3390\/ma4101861"},{"key":"37","doi-asserted-by":"crossref","unstructured":"40. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech. 2006; 7:67.","DOI":"10.1208\/pt070367"},{"key":"38","doi-asserted-by":"crossref","unstructured":"41. Nasatto PL, Pignon F, Silveira JL, Duarte MER, Noseda MD, Rinaudo M. Methylcellulose, a cellulose derivative with original physical properties and extended applications. Polymers. 2015; 7:777-803.","DOI":"10.3390\/polym7050777"},{"key":"39","doi-asserted-by":"crossref","unstructured":"42. Kaushal G, Sayre BE, Prettyman T. Stability-indicating HPLC method for the determination of the stability of oxytocin parenteral solutions prepared in polyolefin bags. Drug Discov Ther. 2012; 6:49-54.","DOI":"10.5582\/ddt.2012.v6.1.49"},{"key":"40","doi-asserted-by":"crossref","unstructured":"43. Washington N, Steele R, Jackson S, Bush D, Mason J, Gill D, Pitt K, Rawlins D. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm. 2000; 198:139-146.","DOI":"10.1016\/S0378-5173(99)00442-1"},{"key":"41","unstructured":"44. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: A review. J Pharm Pharm Sci. 2003; 6:252-273."},{"key":"42","doi-asserted-by":"crossref","unstructured":"45. Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev. 1998; 29:39-49.","DOI":"10.1016\/S0169-409X(97)00060-4"},{"key":"43","doi-asserted-by":"crossref","unstructured":"46. Salib R, Lau L, Howarth P. The novel use of the human nasal epithelial cell line RPMI 2650 as an <i>in vitro<\/i> model to study the influence of allergens and cytokines on transforming growth factor-\u03b2 gene expression and protein release. Clin Exp Allergy. 2005; 35:811-819.","DOI":"10.1111\/j.1365-2222.2005.02258.x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"48. Wengst A, Reichl S. RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as <i>in vitro<\/i> models for nasal permeation studies. Eur J Pharm Biopharm. 2010; 74:290-297.","DOI":"10.1016\/j.ejpb.2009.08.008"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/12\/3\/12_2018.01017\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T01:01:27Z","timestamp":1531530087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/12\/3\/12_2018.01017\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,30]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2018.01017","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,30]]}}}